# Incidence of Hypophosphatemia After Treatment With Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia

> **NCT03238911** · PHASE3 · COMPLETED · sponsor: **Pharmacosmos A/S** · enrollment: 123 (actual)

## Conditions studied

- Iron Deficiency Anaemia
- Iron Deficiency Anemia

## Interventions

- **DRUG:** Iron isomaltoside/ferric derisomaltose
- **DRUG:** Ferric carboxymaltose

## Key facts

- **NCT ID:** NCT03238911
- **Lead sponsor:** Pharmacosmos A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-24
- **Primary completion:** 2018-06-19
- **Final completion:** 2018-06-19
- **Target enrollment:** 123 (ACTUAL)
- **Last updated:** 2020-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03238911

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03238911, "Incidence of Hypophosphatemia After Treatment With Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03238911. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*